TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Maximum Observed Concentration (Cmax) of AG-881 Formulation 1 without Food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Total Plasma Clearance After Oral (Extravascular) Administration (CL/F) of AG-881 Formulation 1 without Food
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of early enteral feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: improvement of muscle function (hand grip strength, respiratory muscle function)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Smoking status at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Response (CR) and Complete Response with Incomplete Blood Count Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of concentration of omega-3 fatty acids in blood plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Prevalence of Expiratory Flow Limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in glycosylated hemoglobin A1C (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dindo-Claviens classification
Endpoint domain: Adverse events/effects
Primary endpoint: EORTC QLQ-CR30 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: EORTC QLQ-CR29 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: LARS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Variation in travel speed of the center of pressure (COP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brain MRI results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under concentration-time curve from time zero to the last sampling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under concentration-time curve from time zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective response ratio (Complete response (CR) and partial response (PR))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Feasibility of CD19 CAR T cell production
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Rescue Inhaler Actuations/Person/Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Analgesic effects measured by visual analog scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children with Respiratory Tract Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Height at the age of 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Weight Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of cardiac toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Reported Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of a break in the skin wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surface electromyographic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8+/FOXP3+ relative change of lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Insulin area under the curve (oral glucose tolerance test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body composition (% body fat, visceral fat)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with remission (HAM-D score ≤ 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) for cenerimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful 5th Metatarsal Unions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Completion of the study with acceptable image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 2.4 km completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of IL-6, IL-10 and TNFα
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of AIDS defining OIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic sensitivity of ctDNA methylation sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic specificity of ctDNA methylation sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Emergency and Hospital visits during chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients not receiving full treatment due to intolerance to PMZ-1620
Endpoint domain: Adverse events/effects
Primary endpoint: Spectral resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berlin Social Support Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Baseline Vaginal Bleeding Who Experienced ≥ 50% Reduction in the Number of Vaginal Bleeding Days on Treatment Compared to Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Baseline Vaginal Bleeding Who Experienced Cessation of Vaginal Bleeding Over a 6-month Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain measured by VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Survival (OS) in the PD-L1 CPS ≥1 Population
Endpoint domain: Mortality/survival
Primary endpoint: Overall Survival (OS) in the PD-L1 Expression High (CPS ≥20) Population
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Experiencing Dose-Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Infected With COVID-19 or COVID-19 Like Illness
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of perioperative complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful reversal of reduction in NIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Grade of acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade of chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline in processing speed
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in executive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in episodic memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Filter running time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Range motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxford Shoulder Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) based on dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Average nausea intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal validity measured by HAQ-II scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Perceived Stress Scale (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lactate level in skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 7-Day Self-Reported Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OSA Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of symptoms of mTBI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pelvic Floor Disorders symptoms changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of the Mayo Clinic Foregut Surgery Report Card Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of good breast tissue healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Stroop colour word test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wheelchair Skills Test Version 4.1 (WST) Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of OTP patients HIV tested
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change from baseline in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean 24-hour Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of dd-cfDNA in heart transplant rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Percent of partographs showing suboptimal fetal/newborn outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature change of relevant acupoints or sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of urinary biomarkers FB1 and FB2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implant success rate at one year post implant placement
Endpoint domain: Mortality/survival
Primary endpoint: Implant survival rate at one year post implant placement
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose (MTD) of TCN-PM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-12 Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form-12 Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of agreement between assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in analgesics/opiate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Insulin Need (IU/Kg/Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c Percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Insulin Demand Adjusted for HbA1c %(IDAA1c) <9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bypass Graft Flow Mediated Vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Under-5 mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: 30-day postoperative COVID-19 infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: ST changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Blood Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Urine Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Eating habits changes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on anxiety diagnostic interview after treatment or waitlist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on anxiety rating scale after treatment or waitlist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and efficacy of cryo ablation compared with RF ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in oral bacteria biofilm composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to locoregional recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Time to distant metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Time to recurrence based on original grade and hypoxia
Endpoint domain: Mortality/survival
Primary endpoint: incidence and severity of AEs
Endpoint domain: Adverse events/effects
Primary endpoint: 12 lead ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinically significant abnormal vital signs measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically significant abnormal physical examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in area of indocyanine green fluorescence and radioactive area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-Day All-Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: methamphetamine use
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cell Surface Expression of CS1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of auditory hallucinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from Baseline Adult Suicide Ideation Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in SGK1 mRNA Expression Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in MKP1/DuSP1 mRNA Expression Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful SBC procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Response Rate Defined to be a CR or PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Pneumococcal Polysaccharide Conjugate vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the curve (AUC) in blood for GSK2126458
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum observed concentration (Cmax) in blood for GSK2126458
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pre-dose (trough) concentration at the end of the dosing interval (Ctrough) in blood for GSK2126458
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Non-insulin mediated glucose uptake (NIMGU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Postural Control - Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postural Control - Maximum Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postural Control - Maximum Extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal Oxygen Uptake (VO2max, Absolute Values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Aqueous concentration of Vigamox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of positive and negative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Deployment and procedural outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragmatic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Worst Severity Of Gastrointestinal-Related Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Duration of Gastrointestinal-Related Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in partial pressure of oxygen from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Good positioning of the distal end of the catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of postoperative complications or death after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Hsp90α Concentration of plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute success rate of pulmonary vein isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting Preferred Screening Type
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ethyl glucuronide positive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic Response at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composite score on cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VLDL-TG and FFA balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of arthralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Platelet Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in image features on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in magnetic resonance elastography (MRE) liver tumor stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in percent non-viable/necrotic tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Child Developmental Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Spikes and Sharp Waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of fluoroquinolone resistant enteric bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Levels of Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Eating Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Nasal Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Rating the Intervention 'Acceptable'
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Maximum Keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Bone Mineral Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cartilage contact pressures in the hip joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of CMV retinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: other ocular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Patients' preferences towards anticoagulation treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status